Orimed Pharma Launches PrSolufy, First Liquid Aripiprazole Solution in Canada
Key Insights
Orimed Pharma (search) has launched PrSolufy (search), a new liquid formulation of aripiprazole, marking the first liquid solution alternative to solid forms for Canadian patients.
The liquid formulation addresses clinical needs for patients who require alternatives to solid dosage forms, potentially improving treatment accessibility for psychiatric disorders.
PrSolufy (search) represents the first product in Orimed Pharma (search)'s planned portfolio of liquid solutions, demonstrating the JAMP Pharma Group (search)'s commitment to pharmaceutical innovation in Canada.
Orimed Pharma (search), a Canadian-owned pharmaceutical company and affiliate of JAMP Pharma Corporation, has announced the nationwide launch of PrSolufy (search), a liquid formulation of aripiprazole on the Canadian market. The new therapeutic solution addresses an existing clinical need by providing an alternative to current solid forms for patients requiring different administration options.
Novel Liquid Formulation Addresses Patient Needs
Aripiprazole is an atypical antipsychotic medication used to treat various psychiatric disorders, including schizophrenia (search), bipolar disorder (search) type 1, and major depression (search). The new liquid formulation of PrSolufy (search) was specifically designed to be easy to swallow for patients who may require an alternative to traditional solid dosage forms.
"The launch of PrSolufy (search) perfectly illustrates Orimed Pharma (search)'s mission to make treatments more accessible and tailored to the real needs of patients and healthcare professionals," said Thierry Lavoie, Senior Director at Orimed Pharma.
Strategic Innovation Initiative
PrSolufy (search) represents the first product in what will become a broader portfolio of liquid solutions from Orimed Pharma (search). Louis Pilon, President and CEO of the JAMP Pharma Group (search), emphasized the strategic significance of this launch: "The JAMP Pharma Group is proud to support this innovation, as it allows us to take a first step in developing a portfolio of liquid solutions and thus maintain our commitment to the health of Canadians."
Market Availability and Distribution
The liquid aripiprazole solution is now available nationwide through the Canadian pharmaceutical distribution network. Healthcare professionals can obtain detailed information on prescribing guidelines and product availability by contacting Orimed Pharma (search) directly.
Company Background and Market Position
Orimed Pharma (search), based in Boucherville, Quebec, specializes in developing and marketing innovative therapeutic solutions aimed at improving patient quality of life in Canada. The company operates under the JAMP Pharma Group (search) umbrella, which has experienced exceptional growth over the past decade.
The JAMP Pharma Group (search) has established itself as a significant player in the Canadian pharmaceutical market, with a portfolio of more than 380 molecules and recognition as one of the industry leaders in terms of annual prescription volume. The organization has received authorization from Health Canada for more than 130 new products over the past three years, positioning it as the Canadian leader in product launches and expanding treatment options available to Canadian patients, including specialty drugs.